Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2(8), 584–593 (2002).
  Medline CASGoogle Scholar
• 2 Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11(6), 411–425 (2011).
  Medline CASGoogle Scholar
• 3 Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 12(9), 685–696 (2010).
  Medline CASGoogle Scholar
• 4 Nishimori H, Ehata S, Suzuki HI, Katsuno Y, Miyazono K. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J. Biol. Chem. 287(24), 20037–20046 (2012).
  Medline CASGoogle Scholar
• 5 Zayzafoon M, Abdulkadir SA, McDonald JM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 279(5), 3662–3670 (2004).
  Medline CASGoogle Scholar
• 6 El-Amm J, Aragon-Ching JB. Targeting bone metastases in metastatic castration-resistant prostate cancer. Clin. Med. Insights Oncol. 10(Suppl. 1), 11–19 (2016).
  Medline CASGoogle Scholar
• 7 Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol. 31(5), 578–583 (2000).
  Medline CASGoogle Scholar
• 8 Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
  Medline CASGoogle Scholar
• 9 Price PA, Toroian D, Chan WS. Tissue-nonspecific alkaline phosphatase is required for the calcification of collagen in serum: a possible mechanism for biomineralization. J. Biol. Chem. 284(7), 4594–4604 (2009).
  Medline CASGoogle Scholar
• 10 Cook RJ, Coleman R, Brown J et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 12(11 Pt 1), 3361–3367 (2006).
  Medline CASGoogle Scholar
• 11 Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12(20 Pt 2), 6213s–6216s (2006). • A review of the mechanisms and therapeutic implications of osteolytic and osteoblastic bone metastases.
  Medline CASGoogle Scholar
• 12 D'Oronzo S, Brown J, Coleman R. The value of biomarkers in bone metastasis. Eur. J. Cancer Care 26(6), e12725 (2017). •• A review of the current knowledge of bone metastasis development and recent advances in biomarker research.
  Google Scholar
• 13 Rucci N, Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front. Biosci. 2, 907–915 (2010). • A review of bone metastases and osteomimicry.
  Google Scholar
• 14 Lin DL, Tarnowski CP, Zhang J et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47(3), 212–221 (2001).
  Medline CASGoogle Scholar
• 15 Knerr K, Ackermann K, Neidhart T, Pyerin W. Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int. J. Cancer 111(1), 152–159 (2004).
  Medline CASGoogle Scholar
• 16 Zhau HE, He H, Wang CY et al. Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin. Cancer Res. 17(8), 2159–2169 (2011).
  Medline CASGoogle Scholar
• 17 Bitting RL, Armstrong AJ. Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. Cancer J. 19(1), 25–33 (2013).
  Medline CASGoogle Scholar
• 18 Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97(1), 59–69 (2005).
  Medline CASGoogle Scholar
• 19 Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925–4935 (2005).
  Medline CASGoogle Scholar
• 20 Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 14(8), 816–827 (2009).
  Medline CASGoogle Scholar
• 21 Fizazi K, Massard C, Smith M et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur. Urol. 68(1), 42–50 (2015). •• Analysis of a contemporary metastatic castration-resistant prostate cancer dataset that identified bone-related parameters associated with longer survival.
  MedlineGoogle Scholar
• 22 Guinney J, Wang T, Laajala TD et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 18(1), 132–142 (2017).
  MedlineGoogle Scholar
• 23 Halabi S, Lin CY, Small EJ et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J. Natl Cancer Inst. 105(22), 1729–1737 (2013).
  Medline CASGoogle Scholar
• 24 Halabi S, Lin CY, Kelly WK et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 32(7), 671–677 (2014).
  MedlineGoogle Scholar
• 25 Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol. Oncol. 35S, S1–S13 (2017).
  MedlineGoogle Scholar
• 26 Metwalli AR, Rosner IL, Cullen J et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol. Oncol. 32(6), 761–768 (2014). • Retrospective study of ALP velocity as an independent predictor of overall survival and bone metastases–free survival in patients with CRPC.
  Medline CASGoogle Scholar
• 27 Hammerich KH, Donahue TF, Rosner IL et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urol. Oncol. 35(7), 460.e421–460.e428 (2017).
  Google Scholar
• 28 Boegemann M, Schrader AJ, Krabbe LM, Herrmann E. Present, emerging and possible future biomarkers in castration resistant prostate cancer (CRPC). Curr. Cancer Drug Targets 15(3), 243–255 (2015).
  Medline CASGoogle Scholar
• 29 Petrylak DP, Crawford ED. Biomarkers for the management of castration-resistant prostate cancer: we are not there yet. Target Oncol. 12(4), 401–412 (2017). •• A review of existing and potential biomarkers for managing CRPC.
  MedlineGoogle Scholar
• 30 Mulders PF, De Santis M, Powles T, Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol. Immunother. 64(6), 655–663 (2015).
  Medline CASGoogle Scholar
• 31 Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580–593 (2010).
  Medline CASGoogle Scholar
• 32 Gulley JL, Madan RA, Pachynski R et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl. Cancer Inst. 109(4), doi:10.1093/jnci/djw261 (2017).
  MedlineGoogle Scholar
• 33 Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid. 10, 1–10 (2015).
  Medline CASGoogle Scholar
• 34 No authors listed. Provenge^® (sipuleucel-T) suspension for intravenous infusion [prescribing information]. Dendreon Corporation, WA, USA (2010).
  Google Scholar
• 35 Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des. Devel. Ther. 6, 13–18 (2012).
  Medline CASGoogle Scholar
• 36 Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res. Rep. Urol. 6, 97–105 (2014).
  Medline CASGoogle Scholar
• 37 Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag. Res. 6, 39–51 (2014).
  MedlineGoogle Scholar
• 38 Iuliani M, Pantano F, Buttigliero C et al. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget 6(14), 12520–12528 (2015).
  MedlineGoogle Scholar
• 39 Alex AB, Pal SK, Agarwal N. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 8(4), 267–275 (2016).
  Medline CASGoogle Scholar
• 40 No authors listed. Zytiga^™ (abiraterone acetate) tablets for oral administration [prescribing information]. Centocor Ortho Biotech, Inc., PA, USA (2011).
  Google Scholar
• 41 Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 117(2), 215–225 (2016).
  Medline CASGoogle Scholar
• 42 Patel NK, Finianos A, Whitaker KD, Aragon-Ching JB. Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. Ther. Clin. Risk Manag. 10, 651–664 (2014).
  Medline CASGoogle Scholar
• 43 Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787–790 (2009).
  Medline CASGoogle Scholar
• 44 No authors listed. Xtandi^® (enzalutamide) capsules for oral use [prescribing information]. Astellas Pharma US Inc., IL, USA (2012).
  Google Scholar
• 45 Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol. 28(4 Suppl. 15), 3–7 (2001).
  Medline CASGoogle Scholar
• 46 Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin. Oncol. 26(5 Suppl. 17), 3–7 (1999).
  Medline CASGoogle Scholar
• 47 Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70(20), 7992–8002 (2010).
  Medline CASGoogle Scholar
• 48 Fitzpatrick JM, De Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur. Urol. 65(6), 1198–1204 (2014).
  Medline CASGoogle Scholar
• 49 Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 69(14), 1579–1585 (2009).
  Medline CASGoogle Scholar
• 50 No authors listed. Taxotere (docetaxel) injection concentrate, intravenous infusion [prescribing information]. Sanofi-Aventis US LLC, NJ, USA (2015).
  Google Scholar
• 51 Mellado B, Jimenez N, Marin-Aguilera M, Reig O. Diving into cabazitaxel's mode of action: more than a taxane for the treatment of castration-resistant prostate cancer patients. Clin. Genitourin. Cancer 14(4), 265–270 (2016).
  MedlineGoogle Scholar
• 52 Zhao S, Yu EY. Castrate-resistant prostate cancer: postdocetaxel management. Curr. Opin. Urol. 23(3), 201–207 (2013).
  MedlineGoogle Scholar
• 53 Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat. Rev. Drug Discov. 9(9), 677–678 (2010).
  Medline CASGoogle Scholar
• 54 No authors listed. Jevtana (cabazitaxel) injection, 60 mg/1.5 ml, for intravenous infusion only [prescribing information]. Sanofi-Aventis U.S. LLC, NJ, USA (2010).
  Google Scholar
• 55 Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting ²²³Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62(11), 3120–3125 (2002).
  Medline CASGoogle Scholar
• 56 Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting ²²³Ra: comparison with the beta-emitter ⁸⁹Sr in mice. J. Nucl. Med. 44(2), 252–259 (2003).
  Medline CASGoogle Scholar
• 57 Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter ²²³Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12(20 Pt 2), 6250s–6257s (2006).
  Medline CASGoogle Scholar
• 58 Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DL. Whole-body and microenvironmental localization of radium-223 in naive and mouse models of prostate cancer metastasis. J. Natl Cancer Inst. 108(5), djv380 (2016).
  MedlineGoogle Scholar
• 59 Suominen MI, Fagerlund KM, Rissanen JP et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin. Cancer Res. 23(15), 4335–4336 (2017).
  Medline CASGoogle Scholar
• 60 Suominen MI, Rissanen JP, Kakonen R et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J. Natl Cancer Inst. 105(12), 908–916 (2013).
  MedlineGoogle Scholar
• 61 Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Sublethal exposure to alpha radiation (²²³Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget 7(52), 86937–86947 (2016).
  MedlineGoogle Scholar
• 62 No authors listed. Xofigo (radium Ra 223 dichloride) Injection, for intravenous use [prescribing information]. Bayer HealthCare Pharmaceuticals Inc., NJ, USA (2013).
  Google Scholar
• 63 Bilen MA, Hess KR, Subudhi SK et al. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother. Pharmacol. 80(3), 583–589 (2017).
  Medline CASGoogle Scholar
• 64 Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213–223 (2013).
  Medline CASGoogle Scholar
• 65 Sartor O, Coleman RE, Nilsson S et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the Phase 3 ALSYMPCA trial with radium-223. Ann. Oncol. 28(5), 1090–1097 (2017).
  Medline CASGoogle Scholar
• 66 Saad F, Carles J, Gillessen S et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm Phase 3b trial. Lancet Oncol. 17(9), 1306–1316 (2016).
  Medline CASGoogle Scholar
• 67 George DJ, Nabhan C, Devries T, Whitmore JB, Gomella LG. Survival outcomes of sipuleucel-T Phase III studies: impact of control-arm cross-over to salvage immunotherapy. Cancer Immunol. Res. 3(9), 1063–1069 (2015).
  Medline CASGoogle Scholar
• 68 Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13(10), 983–992 (2012).
  Medline CASGoogle Scholar
• 69 Chi KN, Kheoh T, Ryan CJ et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann. Oncol. 27(3), 454–460 (2016).
  Medline CASGoogle Scholar
• 70 Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 16(2), 152–160 (2015).
  Medline CASGoogle Scholar
• 71 Mikah P, Krabbe LM, Eminaga O et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer 16, 214 (2016).
  MedlineGoogle Scholar
• 72 Armstrong AJ, Garrett-Mayer ES, Yang YC, De Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 13(21), 6396–6403 (2007).
  Medline CASGoogle Scholar
• 73 Armstrong AJ, Garrett-Mayer E, De Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 16(1), 203–211 (2010).
  Medline CASGoogle Scholar
• 74 Sonpavde G, Pond GR, Berry WR et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol. Oncol. 30(5), 607–613 (2012).
  Medline CASGoogle Scholar
• 75 Bahl A, Oudard S, Tombal B et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann. Oncol. 24(9), 2402–2408 (2013).
  Medline CASGoogle Scholar
• 76 Van Soest RJ, Nieuweboer AJ, De Morree ES et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur. J. Cancer 51(17), 2562–2569 (2015).
  Medline CASGoogle Scholar
• 77 Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  Medline CASGoogle Scholar
• 78 Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089–3094 (2006).
  Medline CASGoogle Scholar
• 79 Rathkopf DE, Smith MR, De Bono JS et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 66(5), 815–825 (2014).
  Medline CASGoogle Scholar
• 80 De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011).
  Medline CASGoogle Scholar
• 81 Logothetis CJ, Basch E, Molina A et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13(12), 1210–1217 (2012).
  Medline CASGoogle Scholar
• 82 Ryan CJ, Smith MR, De Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138–148 (2013).
  Medline CASGoogle Scholar
• 83 Verzoni E, De Giorgi U, Derosa L et al. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget 7(26), 40085–40094 (2016).
  MedlineGoogle Scholar
• 84 Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424–433 (2014).
  MedlineGoogle Scholar
• 85 Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
  Medline CASGoogle Scholar
• 86 Salvi S, Casadio V, Conteduca V et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget 7(25), 37839–37845 (2016).
  MedlineGoogle Scholar
• 87 Yamashita S, Kohjimoto Y, Iguchi T et al. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol. 16, 13 (2016).
  MedlineGoogle Scholar
• 88 Quinn DI, Tangen CM, Hussain M et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised Phase 3 trial. Lancet Oncol. 14(9), 893–900 (2013).
  Medline CASGoogle Scholar
• 89 Lara PN Jr, Ely B, Quinn DI et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J. Natl Cancer Inst. 106(4), dju013 (2014).
  MedlineGoogle Scholar
• 90 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).
  Medline CASGoogle Scholar
• 91 Han KS, Hong SJ. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis. J. Cancer Res. Clin. Oncol. 140(10), 1769–1776 (2014).
  Medline CASGoogle Scholar
• 92 Matsuyama H, Shimabukuro T, Hara I et al. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int. J. Clin. Oncol. 19(5), 946–954 (2014).
  Medline CASGoogle Scholar
• 93 De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010).
  Medline CASGoogle Scholar
• 94 Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled Phase II study. Lancet Oncol. 8(7), 587–594 (2007).
  Medline CASGoogle Scholar
• 95 Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 11(12), 4451–4459 (2005).
  Medline CASGoogle Scholar
• 96 Nilsson S, Strang P, Aksnes AK et al. A randomized, dose-response, multicenter Phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48(5), 678–686 (2012).
  Medline CASGoogle Scholar
• 97 Cook G Jr., Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. ¹⁸F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with ²²³Ra-chloride (Alpharadin). EJNMMI Res. 1(1), 4 (2011).
  MedlineGoogle Scholar
• 98 Uemura H, Uemura H, Matsubara N et al. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. Int. J. Clin. Oncol. 22(5), 954–963 (2017).
  Medline CASGoogle Scholar
• 99 Miyazaki KS, Kuang Y, Kwee SA. Changes in skeletal tumor activity on ¹⁸F-choline PET/CT in patients receiving ²²³radium radionuclide therapy for metastatic prostate cancer. Nucl. Med. Mol. Imaging 49(2), 160–164 (2015).
  Medline CASGoogle Scholar
• 100 Scalzi P, Baiocco C, Genovese S, Trevisan A, Sirotova Z, Poti C. Evaluation of bone metastases by ¹⁸F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223. Urologia 84(1), 61–64 (2017).
  MedlineGoogle Scholar
• 101 Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase 3, double-blind, randomised trial. Lancet Oncol. 15(7), 738–746 (2014).
  Medline CASGoogle Scholar
• 102 Heinrich D, Gillessen S, Heidenreich A et al. Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Poster presented at the ESMO Congress, 7–11 October 2016, Copenhagen, Denmark. www.poster-submission.com/esmo2016/visitors/carousel.
  Google Scholar